نتایج جستجو برای: kras

تعداد نتایج: 7276  

2016
Christopher J. Tape Stephanie Ling Maria Dimitriadi Kelly M. McMahon Jonathan D. Worboys Hui Sun Leong Ida C. Norrie Crispin J. Miller George Poulogiannis Douglas A. Lauffenburger Claus Jørgensen

Oncogenic mutations regulate signaling within both tumor cells and adjacent stromal cells. Here, we show that oncogenic KRAS (KRAS(G12D)) also regulates tumor cell signaling via stromal cells. By combining cell-specific proteome labeling with multivariate phosphoproteomics, we analyzed heterocellular KRAS(G12D) signaling in pancreatic ductal adenocarcinoma (PDA) cells. Tumor cell KRAS(G12D) eng...

Journal: :Cancer research 2010
Shuangni Yu Zhaohui Lu Changzheng Liu Yunxiao Meng Yihui Ma Wugan Zhao Jianping Liu Jia Yu Jie Chen

Therapeutic applications of microRNA (miRNA) in KRAS-driven pancreatic cancers might be valuable, but few studies have explored this area. Here, we report that miR-96 directly targets the KRAS oncogene and functions as a tumor-suppressing miRNA in pancreatic cancer cells. Ectopic expression of miR-96 through a synthetic miRNA precursor inhibited KRAS, dampened Akt signaling, and triggered apopt...

Journal: :Cell 2012
Haoqiang Ying Alec C. Kimmelman Costas A. Lyssiotis Sujun Hua Gerald C. Chu Eliot Fletcher-Sananikone Jason W. Locasale Jaekyoung Son Hailei Zhang Jonathan L. Coloff Haiyan Yan Wei Wang Shujuan Chen Andrea Viale Hongwu Zheng Ji-hye Paik Carol Lim Alexander R. Guimaraes Eric S. Martin Jeffery Chang Aram F. Hezel Samuel R. Perry Jian Hu Boyi Gan Yonghong Xiao John M. Asara Ralph Weissleder Y. Alan Wang Lynda Chin Lewis C. Cantley Ronald A. DePinho

Tumor maintenance relies on continued activity of driver oncogenes, although their rate-limiting role is highly context dependent. Oncogenic Kras mutation is the signature event in pancreatic ductal adenocarcinoma (PDAC), serving a critical role in tumor initiation. Here, an inducible Kras(G12D)-driven PDAC mouse model establishes that advanced PDAC remains strictly dependent on Kras(G12D) expr...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2015
Frank McCormick

KRAS proteins play a major role in human cancer, but have not yielded to therapeutic attack. New technologies in drug discovery and insights into signaling pathways that KRAS controls have promoted renewed efforts to develop therapies through direct targeting of KRAS itself, new ways of blocking KRAS processing, or by identifying targets that KRAS cancers depend on for survival. Although drugs ...

Journal: :The Journal of Cell Biology 2005
Marc Fivaz Tobias Meyer

The Ras/MAPK pathway regulates synaptic plasticity and cell survival in neurons of the central nervous system. Here, we show that KRas, but not HRas, acutely translocates from the plasma membrane (PM) to the Golgi complex and early/recycling endosomes in response to neuronal activity. Translocation is reversible and mediated by the polybasic-prenyl membrane targeting motif of KRas. We provide e...

Journal: :Cancer discovery 2014
Zehua Zhu Amir R Aref Travis J Cohoon Thanh U Barbie Yu Imamura Shenghong Yang Susan E Moody Rhine R Shen Anna C Schinzel Tran C Thai Jacob B Reibel Pablo Tamayo Jason T Godfrey Zhi Rong Qian Asher N Page Karolina Maciag Edmond M Chan Whitney Silkworth Mary T Labowsky Lior Rozhansky Jill P Mesirov William E Gillanders Shuji Ogino Nir Hacohen Suzanne Gaudet Michael J Eck Jeffrey A Engelman Ryan B Corcoran Kwok-Kin Wong William C Hahn David A Barbie

Although the roles of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) signaling in KRAS-driven tumorigenesis are well established, KRAS activates additional pathways required for tumor maintenance, the inhibition of which are likely to be necessary for effective KRAS-directed therapy. Here, we show that the IκB kinase (IKK)-related kinases Tank-binding kinase-1 (TBK...

2015
Shaoming Li Lei Zhao Jiahui Zhang Zhiqiang Zou Peng Du

BACKGROUND Kirsten rat sarcoma (KRAS) mutations are widespread in lung adenocarcinoma patients. The combined utilization of KRAS antisense oligodeoxynucleotide (ASODN) and insulin-like growth factor-I receptor (IGF-IR) may inhibit the proliferation of A549 cell lines of lung adenocarcinoma. METHODS Point mutations of the KRAS gene in A549 cells were detected by polymerase chain reaction with ...

Journal: :Molecular cancer research : MCR 2014
Katja Schuster Niranjan Venkateswaran Andrea Rabellino Luc Girard Samuel Peña-Llopis Pier Paolo Scaglioni

UNLABELLED Lung cancer commonly displays a number of recurrent genetic abnormalities, and about 30% of lung adenocarcinomas carry activating mutations in the Kras gene, often concomitantly with inactivation of tumor suppressor genes p16(INK4A) and p14(ARF) of the CDKN2AB locus. However, little is known regarding the function of p15INK4B translated from the same locus. To determine the frequency...

2013
Xiaohong Tan Julian Carretero Zhao Chen Jishuai Zhang Yanxiao Wang Jicheng Chen Xiubin Li Hui Ye Chuanhao Tang Xuan Cheng Ning Hou Xiao Yang Kwok-Kin Wong

Interleukin-6 (IL-6) is involved in lung cancer tumorigenesis, tumor progression, metastasis, and drug resistance. Previous studies show that blockade of IL-6 signaling can inhibit tumor growth and increase drug sensitivity in mouse models. Clinical trials in non-small cell lung cancer (NSCLC) reveal that IL-6 targeted therapy relieves NSCLC-related anemia and cachexia, although other clinical ...

Journal: :Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008
Rafael G Amado Michael Wolf Marc Peeters Eric Van Cutsem Salvatore Siena Daniel J Freeman Todd Juan Robert Sikorski Sid Suggs Robert Radinsky Scott D Patterson David D Chang

PURPOSE Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials. ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید